Related Experiment Video
Updated: Sep 1, 2025
Microvascular Decompression: Salient Surgical Principles and Technical Nuances
Published on: July 5, 2011
Decompressive hemicraniectomy in patients with malignant middle cerebral artery infarction: A real-world study
Fabio Pilato1, Giovanni Pellegrino2, Rosalinda Calandrelli3
1Unit of Neurology, Neurophysiology, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy.
Insights
Decompressive hemicraniectomy (DHC) significantly reduces mortality in malignant middle cerebral artery infarction (mMCA) patients compared to best medical treatment (BMT). While DHC can lead to disability, it is a life-saving option for selected patients.
Area of Science:
- Neurology
- Neurosurgery
- Critical Care Medicine
Background:
- Malignant middle cerebral artery infarction (mMCA) has a high fatality rate (up to 80%).
- Decompressive hemicraniectomy (DHC) is a treatment option to reduce mortality, but often results in severe disability.
- Understanding factors influencing treatment choice and prognosis is crucial for mMCA patients.
Purpose of the Study:
- To analyze baseline characteristics of patients with mMCA undergoing DHC versus best medical treatment (BMT).
- To identify factors associated with the choice between DHC and BMT.
- To determine predictors of prognosis in mMCA patients.
Main Methods:
- Retrospective analysis of clinical and radiological features of 125 mMCA patients.
- Comparison of epidemiological, clinical, and neuroimaging data between DHC and BMT groups.
- Regression analysis to identify predictors of surgical treatment and patient outcomes.
Main Results:
- DHC patients (N=57) were younger and presented with larger infarct volumes and midline shift compared to BMT patients (N=68).
- Treatment choice (DHC vs. BMT) was influenced by age, clinical status (NIHSS), and ventricle volume.
- Mortality during hospitalization was significantly lower in the DHC group (15%) compared to the BMT group (71.7%).
Conclusions:
- DHC is a life-saving therapy for selected mMCA patients, despite potential for prolonged hospitalization and disability.
- Perioperative complications and cost-utility require consideration when deciding on DHC.
- Informed patient and family counseling regarding DHC's short- and long-term consequences is essential.
Background:
Malignant middle cerebral artery infarction (mMCA) is a devastating disease with rates of fatality as high as 80%. Decompressive hemicraniectomy (DHC) reduces mortality, but many survivors inevitably remain severely disabled. This study aimed to analyze patients with mMCA undergoing DHC or best medical treatment (BMT) baseline characteristics and factors linked to therapeutic choice and determinants of prognosis.
Methods:
We recorded clinical and radiological features of patients undergoing BMT or DHC. The two groups were compared for epidemiology, clinical presentation, neuroimaging, and prognosis. Regression analysis was performed to identify predictors of surgical treatment and outcome.
Results:
One hundred twenty-five patients were included (age 67.41 ± 1.39 yo; 65 M). Patients undergoing DHC (N = 57) were younger (DHC 55.71 ± 1.48 yo vs. BMT 77.22 ± 1.38) and had midline shift (DHC 96.5% (55/57) vs. BMT 35.3% (24/68), a larger volume of the affected hemisphere and reduced ventricles volume as compared to BMT. The chance of surgery depended on age (Exp(B) = 0.871, p < 0.001), clinical status at onset (NIHSS Exp(B) = 0.824, p = 0.030) and volume of the ventricle of the affected hemisphere (Exp(B) = 0.736, p = 0.006). Death rate during admission was significantly lower for DHC (DHC 15% (6/41) vs BMT 71.7% (38/53), Fisher's test = 30.234, p < 0.001).
Conclusion:
Although DHC may cause prolonged hospitalization and long-term disabled patients, it is a lifesaving therapy that should be considered for selected patients with mMCA but perioperative complications and cost-utility should be considered. Patients and families should be correctly counseled about this therapeutic choice and its short- and long-term consequences.
